Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-15

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute cough has a 3\~8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.The drug in this study is for post-infection cough in subacute cough. After long-term clinical practice, six traditional Chinese medicines, including Aster, Lonicera japonica, Shegan, dried ginger, mango seed and Schizonepeta tenuifolia, were selected to form Zihua Wenfei Zhisou Decoction. This product has the effect of relieving wind, relieving cough, warming the lung and resolving phlegm. It can be used for the cough syndrome caused by Wind-cold invading lungs syndrome. The aim is to evaluate the efficacy and safety of Zihua Wenfei Zhisou Granule in the treatment of postinfection cough (wind-cold lung syndrome) with placebo as a control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children

NCT04457011

Cough

COMPLETED PHASE2

Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment

NCT06773117

Cough

NOT_YET_RECRUITING PHASE3

The Effect of Huashibaidu Granule on Community-acquired Pneumonia in Children

NCT05711017

Community-acquired Pneumonia

UNKNOWN NA

A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection

NCT02539277

Acute Upper Respiratory Infection

UNKNOWN PHASE4

Jinhua Qinggan Granules in the Treatment of COVID-19

NCT04723524

COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients in treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day). Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients. After that, there will be a follow-up 14 days after drug withdrawal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zihua Wenfei Zhisou Granule

Patients in experimental treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Group Type EXPERIMENTAL

Zihua Wenfei Zhisou Granule

Intervention Type DRUG

14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day

Zihua Wenfei Zhisou Granule-matched placebo

Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Placebo does not contain active pharmaceutical ingredients, and its main ingredients are lactose, beta-cyclodextrin, stevioside, and caramel.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zihua Wenfei Zhisou Granule

14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day

Intervention Type DRUG

Placebo

14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* When signing the informed consent form, the age is between 18 and 65 years old (including 18 and 65 years old)；
* Diagnosis of postinfectious cough;
* Wind-cold invading lungs syndrome in TCM Zheng;
* Baseline cough visual analogue scale of 60 mm or more;
* Cough duration of 3- 6 weeks;
* Voluntarily provide written and informed consent.

Exclusion Criteria

* Cough caused by cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough or any other concomitant conditions;
* Patients with severe pulmonary diseases such as lung cancer, lung tuberculosis, or lung fibrosis;
* After inhaling bronchodilator, patients with FEV1/FVC\<70% were excluded;
* Subjects who have taken angiotensin-converting-enzyme inhibitor (ACEI) in the past month;
* Current smokers or recent ex-smokers quitting smoking less than 3 months ago;
* FeNO ≥ 32 ppb or Bronchial provocation test positive (for FeNO and Bronchial provocation test, if the center cannot detect it, it can be detected in other qualified tertiary hospitals);
* Combined with serious cardio-cerebrovascular diseases, malignant tumors, diseases of blood and hematopoietic system, gastrointestinal diseases or other serious or progressive diseases of the system; Or those who are unable to cooperate or unwilling to cooperate due to severe mental illness, severe cognitive impairment, etc;
* Liver and kidney dysfunction: ALT or AST \>2 times the upper limit of normal reference value; And/or serum creatinine \>1.5 times the upper limit of normal reference value, or eGFR\< 60 mL/min/1.73m2;
* White blood cell count \< 3.0×109/L or \> 10.0×109/L, and/or neutrophil granulocyte \> 80%;
* Patients with temperature of 37.3℃ or above;
* Patients taking similar medications in the last one week;
* Have a long history of alcohol or drug abuse;
* Pregnancy or potential pregnancy or lactation;
* Allergic constitution or known to be allergic to any component in tested drug;
* Patients having participated or participating in another trial in last 3 month;
* Patients unsuitable for clinical trials judged by researchers.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No